Journal ArticleDOI
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
Alkomiet Hasan,Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Florence Thibaut,Hans-Jürgen Möller +7 more
Reads0
Chats0
TLDR
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005 and provide evidence-based practice recommendations that are clinically and scientifically meaningful.Abstract:
These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in 2005. For this 2012 revision, all available publications pertaining to the biological treatment of schizophrenia were reviewed systematically to allow for an evidence-based update. These guidelines provide evidence-based practice recommendations that are clinically and scientifically meaningful and these guidelines are intended to be used by all physicians diagnosing and treating people suffering from schizophrenia. Based on the first version of these guidelines, a systematic review of the MEDLINE/PUBMED database and the Cochrane Library, in addition to data extraction from national treatment guidelines, has been performed for this update. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorised into six levels of evidence (A-F; Bandelow et al. 2008b, World J Biol Psychiatry 9:242). This first part of the updated guidelines covers the general descriptions of antipsychotics and their side effects, the biological treatment of acute schizophrenia and the management of treatment-resistant schizophrenia.read more
Citations
More filters
Journal ArticleDOI
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht,Andrea Cipriani,Andrea Cipriani,Loukia M. Spineli,Dimitris Mavridis,Deniz Örey,Franziska Richter,Myrto Samara,Corrado Barbui,Rolf R. Engel,John R. Geddes,Werner Kissling,Marko Paul Stapf,Bettina Lässig,Georgia Salanti,John M. Davis +15 more
TL;DR: A Bayesian-framework, multiple-treatments meta-analysis of randomised controlled trials to compare 15 antipsychotic drugs and placebo in the acute treatment of schizophrenia found all drugs were significantly more effective than placebo.
Journal ArticleDOI
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Cherrie Galletly,David J. Castle,Frances Dark,Verity Humberstone,Assen Jablensky,Eoin Killackey,Jayashri Kulkarni,Patrick D. McGorry,Olav Nielssen,Nga Tran +9 more
TL;DR: This guideline takes a holistic approach, addressing all aspects of the care of people with schizophrenia and related disorders, not only correct diagnosis and symptom relief but also optimal recovery of social function, and uses a clinical staging model as a framework for recommendations regarding assessment, treatment and ongoing care.
Journal ArticleDOI
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology:
TL;DR: These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia, and cover the pharmacological management and treatment of schizophrenia across the various stages of the illness.
Journal ArticleDOI
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Alkomiet Hasan,Peter Falkai,Thomas Wobrock,Jeffrey A. Lieberman,Birte Glenthøj,Wagner F. Gattaz,Florence Thibaut,Hans-Jürgen Möller,Wfsbp Task Force on Treatment Guidelines for Schizophrenia +8 more
TL;DR: These updated guidelines are based on a first edition of the World Federation of Societies of Biological Psychiatry guidelines for biological treatment of schizophrenia published in 2006 and provide evidence-based practice recommendations that are clinically and scientifically meaningful.
References
More filters
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
TL;DR: In this relatively brief study, the apparently increased comparative risk of agranulocytosis requires that the use of clozapine be limited to selected treatment-resistant patients.
Journal ArticleDOI
What are the functional consequences of neurocognitive deficits in schizophrenia
TL;DR: Verbal memory and vigilance appear to be necessary for adequate functional outcome in schizophrenic patients and may prevent patients from attaining optimal adaptation and hence act as "neurocognitive rate-limiting factors."
Journal ArticleDOI
Practice guideline for the treatment of patients with schizophrenia
Marvin I. Herz,Robert Paul Liberman,T. H. McGlashan,Jeffrey A. Lieberman,Richard Jed Wyatt,Stephen R. Marder,P. Wang,C. Allgulander,Ross J. Baldessarini,R. Balon,A. S. Bellack,C M Jr Berlin,C. H. Blackington,Peter F. Buckley,D. G. Carlson,J. Cott,Francine Cournos,P. Desai,L. Dickstein,Wayne Fenton,W. A. Fisher,Lois T. Flaherty,R. Freedman,Marc Galanter,E. Galton,Rohan Ganguli,L. K. Garrettson,S. Goldfinger,L. S. Goldman,M. Z. Goldstein,T. R. Gordy,S. H. Gray,Monica R. Green,W. M. Greenberg,John G. Gunderson,L. L. Hall,E. Haller,E. Hanin,L. Hawkins,T. W. Hester,T. Horn,J. K. Hsiao,N. V. Juthani,John M. Kane,A. Kayser,H. D. Kibel,R. A. Kimmich,R. R. Koegler,J. Krajeski,T. Kuehnel,J.S. Lamberti,Anthony F. Lehman,J. Leunello,R. L. Martin,R. McCarley,Mark McGee,Herbert Y. Meltzer,M.-Marsel Mesulam,Jeffrey L. Metzner,Loren R. Mosher,J. A. Motto,Kim T. Mueser,R. A. Munoz,H. A. Nasrallah,J. W. Newcomer,Lewis A. Opler,G. N. Peterson,M. Rapaport,Michelle Riba,V. I. Rickert,A. Rifkin,J. S. Rivenbark,S. Robertson,P. Ruiz,W. G. Ryan,M. O. Sanderson,R. B. Schiffer,P. M. Schyve,R. H. Sebring,W. W. Shen,D. Shore,G. M. Simpson,H. E. Soufi,L. I. Stein,N. Stotland,J. Strauss,D. Sundberg,D. Svendsen,Mauricio Tohen,M. Tsuang,J. G. Wagnitz,Richard D. Weiner,W. D. Weitzel,L. J. Wilkerson,D. Wingerson,C A Jr Zarate,J. Zito,Howard Zonana +97 more
Journal ArticleDOI
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht,Caroline Corves,Caroline Corves,Dieter Arbter,Rolf R. Engel,Chunbo Li,Chunbo Li,John M. Davis +7 more
TL;DR: A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost.